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ABSTRACT
Background and Purpose. In rat middle cerebral arteries, endothelium-dependent
hyperpolarization (EDH) is mediated by activation of calcium-activated potassium
(KCa) channels specifically KCa2.3 and KCa3.1. Lipoxygenase (LOX) products func-
tion as endothelium-derived hyperpolarizing factors (EDHFs) in rabbit arteries
by stimulating KCa2.3. We investigated if LOX products contribute to EDH in rat
cerebralarteries.
Methods. Arachidonic acid (AA) metabolites produced in middle cerebral arteries
were measured using HPLC and LC/MS. Vascular tension and membrane poten-
tial responses to SLIGRL were simultaneously recorded using wire myography and
intracellularmicroelectrodes.
Results. SLIGRL, an agonist at PAR2 receptors, caused EDH that was inhibited by a
combinationofKCa2.3andKCa3.1blockade.Non-selectiveLOX-inhibitionreduced
EDH, whereas inhibition of 12-LOX had no effect. Soluble epoxide hydrolase (sEH)
inhibition enhanced the KCa2.3 component of EDH. Following NO synthase (NOS)
inhibition,theKCa2.3componentofEDHwasabsent.UsingHPLC,middlecerebral
arteries metabolized 14C-AA to 15- and 12-LOX products under control conditions.
With NOS inhibition, there was little change in LOX metabolites, but increased
F-typeisoprostanes.8-iso-PGF2α inhibitedtheKCa2.3componentofEDH.
Conclusions. LOX metabolites mediate EDH in rat middle cerebral arteries. Inhi-
bition of sEH increases the KCa2.3 component of EDH. Following NOS inhibition,
loss of KCa2.3 function is independent of changes in LOX production or sEH in-
hibition but due to increased isoprostane production and subsequent stimulation
of TP receptors. These findings have important implications in diseases associated
withlossofNOsignalingsuchasstroke;whereinhibitionofsEHand/orisoprostane
formationmayofbenefit.
Subjects Biochemistry, Biophysics, Anatomy and Physiology, Pharmacology
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Endothelium dependent hyperpolarization (EDH) is an extremely important vasodilator
pathway,particularlyinresistancesizearteries,andhasamajorroleinregulationofblood
pressure; as such the EDH pathway has become intensively studied and targeting this
pathway could result in new classes of antihypertensive and possibly antithrombotic
therapies (Kohler, Kaistha & Wulff, 2010; Kr¨ otz et al., 2010). The exact nature of EDH is
still unresolved but involves several different mechanisms that include release of diffusible
factors(endotheliumderivedhyperpolarizingfactors;EDHFs)(Momboulietal.,1996),di-
rect myo-endothelial cell coupling via gap junctions (Sandow et al., 2002) and increases in
extracellular potassium concentration in the myo-endothelial space (Edwards et al., 1998)
that all result in smooth muscle cell hyperpolarization. The relative contribution of each
mechanismvariesbetweenvascularbedsandspecies(Edwards,Feletou&Weston,2010).
Despite heterogeneity in the pathway, a feature of EDH responses in most vascular
beds is the critical role of endothelial cell calcium-activated potassium channels (KCa).
Blockade of both KCa2.3 (SKCa) and KCa3.1 (IKCa) is required to fully inhibit EDH
responses (Edwards, Feletou & Weston, 2010). In contrast, in the rat middle cerebral artery
(MCA), inhibition of KCa3.1 channels alone is sufficient to fully block the EDH response
obtained but only if NO synthase (NOS) is inhibited (Marrelli, Eckmann & Hunte, 2003;
McNeish, Dora & Garland, 2005). KCa2.3 channels are expressed in the endothelium of
MCA (Cipolla et al., 2009; McNeish et al., 2006) and contribute to EDH of smooth muscle
cells(SMC)invesselsthatareabletosynthesizeNO(McNeishetal.,2006).KCa2.3channel
function is lost following inhibition of NOS (McNeish et al., 2006), but can be restored
upon inhibition of the thromboxane prostanoid (TP) receptor and associated subsequent
Rhokinasemediatedsignalling(McNeish&Garland,2007;McNeishetal.,2012).
In the MCA, EDH responses are also attenuated by inhibition of PLA2 suggesting a
role for a metabolite of arachidonic acid (AA) (Marrelli et al., 2007; McNeish & Garland,
2007; You, Marrelli & Bryan, 2002). A similar inhibition of EDH by PLA2 inhibitors has
also been reported in peripheral arterial beds including mesenteric and coronary arteries
(Hecker et al., 1994; Hutcheson et al., 1999). AA metabolism is complex and produces
a large number of biologically active metabolites that affect vascular tone (Campbell
& Falck, 2007). AA metabolites produced by the cyclooxygenase (COX), epoxygenase
and lipoxygenase (LOX) pathways modulate KCa. The 12- and 15-LOX pathways of
AA metabolism have been implicated in the EDH response (Campbell et al., 1996;
Chawengsub, Gauthier & Campbell, 2009; Nithipatikom et al., 2001a). Metabolites of
15-LOX, 15-hydroxy-11,12-epoxyeicosatrienoic acid (HEETA) and its soluble epoxide
hydrolase (sEH) metabolite, 11,12,15-trihydroxyeicosatrienoic acid (THETA), have been
characterizedasEDHFsinrabbitarterieswheretheystimulateKCa2.3channels(Campbell
& Gauthier, 2013). Rats express a LOX that has both 12- and 15-LOX activity (Watanabe
et al., 1993). Therefore, it is possible that LOX metabolites acting on KCa2.3 could also
contributeEDHintheratMCA.
NOcanpotentiallyinteractwiththesynthesisofmanyAAmetabolitesbybindingtothe
hemegroupoftheseenzymes(Minamiyamaetal.,1997).Therefore,TPreceptor-mediated
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toalteredsynthesisofAAmetabolitessuchasthromboxaneA2 (TxA2)orisoprostanesthat
stimulate the TP receptor. Alternately following inhibition of NOS, there may be a change
inproductionofAAmetabolitesthatnormallystimulateKCa2.3.
As changes in AA metabolism following inhibition of NOS could potentially affect
KCa2.3 function in the MCA, these studies were designed to identify the AA metabolites
anddetermineifthesemetabolitescontributetoEDHintheMCA.Second,weinvestigated
theeffectofNOSinhibitiononAAmetabolismandifanychangeinmetaboliteproduction
contributestothelossofKCa2.3function.
MATERIALS AND METHODS
Male Wistar or Sprague Dawley rats (200–300 g, circa 8–10 weeks old) were humanely
killed in accordance with local ethics committee guidelines. The brain was removed and
immediately placed in ice-cold Krebs’ solution. Segments of the middle cerebral artery
(∼2 mm long) were dissected and stored in ice-cold Krebs’ for use (usually within 30 min
but if first vessel failed to meet the exclusion criteria detailed below a second vessel would
bemountedthiswasnever>4h),withsimilarsizevesselsusedinallexperimentalgroups.
Simultaneous measurement of membrane potential and tension
Smooth muscle membrane potential was measured simultaneously with vasomotor
responses using isometric recording technique. Segments of MCA (internal diameter
∼150 µm) were mounted in a Mulvany–Halpern myograph (model 400A; Danish
Myotechnology) in Krebs’ solution containing (mM): NaCl, 118.0, NaCO3, 24; KCl,
3.6; MgSO4·7H2O, 1.2; glucose, 11.0; CaCl2, 2.5; gassed with 21% O2, 5% CO2, balance
N2 and maintained at 37 ◦C. After equilibration for 20 min, vessels were tensioned to
1–1.5mN(approximateswalltensionat60mmHg).Smoothmuscletensionwasrecorded
with an isometric pressure transducer and Powerlab software (ADI, Australia). Vessel
viability was assessed by adding exogenous K+ (15–55 mM, total K+ concentration);
only vessels developing tension of ≥3 mN were used. Endothelial cell viability was
assessed by the ability of an agonist of protease activated receptor 2, SLIGRL (serine,
leucine, isoleucine, glycine, arginine, leucine; 20 µM) to relax spontaneous tone and to
hyperpolarize the smooth muscle cell membrane by >15 mV. SLIGRL was chosen to
stimulate the endothelium as more commonly used agonists such as ACh are unable to
evoke an EDH response in the MCA and purinergic agonists that can stimulate EDH
responsesevokeconstrictionviasmoothmusclecellaction.
All endothelium-dependent responses to SLIGRL (20 µM) were obtained in resting
vessels with no vasoconstrictor stimulus other than spontaneous tone unless stated
otherwise. EDH of smooth muscle cells was assessed in the presence of the KCa channel
blockers, apamin (KCa2.3, 50 nM), TRAM-34 (KCa3.1, 1 µM) and iberiotoxin (KCa1.1,
100 nM). The effect of KCa blockers on EDH responses was also assessed after addition of
three structurally distinct non-selective inhibitors of LOX (ebselen, nordihydroguaiaretic
acid (NGDA), both 1 µM, and PD146176, 5 µM), soluble epoxide hydrolase (sEH)
inhibitor tAUCB (10 µM) and isoprostane isoPGF2α (1 µM). Isolated EDH responses
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experiments, the effect of the KCa channel blockers was assessed on EDH responses
induced by SLIGRL (20 µM) in the presence of tAUCB or tempol (100 µM). Papaverine
(150µM)wasaddedattheendofeachexperimenttoassessoveralltoneandallrelaxations
are expressed as a percentage of this maximal relaxation. All drugs were allowed to
equilibrateforatleast20minbeforeEDHresponseswerestimulated.Inmostexperiments,
smooth muscle membrane potential (Em) and tension were measured simultaneously
as previously described, using glass microelectrodes (filled with 2 M KCl; tip resistance,
80–120 MΩ) to measure Em (Garland & McPherson, 1992). In experiments where vessels
were able to synthesise NO we only reported EDH of the smooth muscle cell layer as NO
wasabletoevokerelaxationevenifEDHwasblocked.
Measurement of metabolites of 14C-labelled AA
Rat cerebral arteries were dissected, cleaned, cut into 2–3 mm rings, and incubated at
37 ◦C with indomethacin (10 µM) and vehicle or indomethacin and L-NAME (100 µM)
in 2 ml of N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) buffer (mM):
10 HEPES, 150 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 6 glucose, pH 7.4. After 10 min, [14C]-AA
(0.5 µCi, 10−7 M) was added, incubation was continued for 5 min, and then A23187
(10 µM) was added. After 15 min, the reaction was stopped with ethanol (15% final
concentration). The incubation buffer was removed and extracted using Bond Elute
octadecylsilyl columns as previously described (Pfister et al., 1998). The extracts of the
mediawereanalyzedbyreversephasehigh-pressureliquidchromatography(HPLC)using
a Nucleosil C-18 (5µ, 4.6×250 mm) column (Pfister et al., 1998). Solvent system 1 was
usedtoresolvelipoxygenaseandepoxygenasemetabolitesandconsistedofa40minlinear
gradient (flow rate = 1 ml/min) from 50% solvent B (acetonitrile with 0.1% glacial acetic
acid) in solvent A (deionized water) to 100% solvent B. Column effluent was collected in
0.2 ml fractions, and the radioactivity was determined. In a separate series of incubations,
arterial rings were incubated with vehicle or L-NAME (100 µM) as described above.
Following extraction of the media, prostaglandins and isoprostanes were resolved using
aNucleosilC-18columnusingsolventsystem2.Thissolventsystemconsistedofan40min
isocratic elution with 31% solvent B (acetonitrile) in solvent A (water containing 0.025 M
phosphoricacid)followedbya20minlineargradientto100%Banda10minelutionwith
100%B.Thecolumneluatewascollectedin0.5mlfractionsandradioactivitydetermined.
Totalradioactivityfromasamplewasnormalizedtotissueweight.
The extracts were analyzed using liquid chromatography–mass spectrometry (LC/MS)
with an Agilent Model 1100SL mass selective detector and electrospray ionization
(Nithipatikom et al., 2001b; Nithipatikom et al., 2003). Metabolites were resolved using
a Kromasil C-18 (5 µm, 2 × 250 mm) column. Solvent system 3 consisted of a 10 min
linear gradient from 15% solvent B (acetonitrile) in solvent A (water containing 0.005%
glacial acetic acid) to 60% solvent B in A, a 10 min linear gradient to 80% solvent B in
A followed by 5 min gradient to 100% B. The flow rate was 0.2 ml/min. The drying gas
flow was 12 l/min. The nebulizer pressure was 35 psig, vaporizer temperature was 325 ◦C
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voltagewas120V.Detectionwasinthenegativeionmode.Forisoprostanes,theeluatewas
monitored at m/z 351 (M-H) for PGE2-type isoprostanes and m/z 353 for PGF2-type
isoprostanes. Comparisons were made with the elution times of known isoprostane
standards.
Data analysis and statistical procedures
Results are expressed as the mean ± s.e.m. of n animals. Tension values are given in mN
(always per 2 mm segment) and Em as mV. Vasodilatation is expressed as percentage
reduction of the total vascular tone (spontaneous tone plus vasoconstrictor response),
quantified by relaxation with papaverine (150 µM). Graphs were drawn and comparisons
made using one-way ANOVA with Tukeys’ post-test or Students’ t-test, as appropriate
(Prism,GraphPad).P ≤ 0.05wasconsideredsignificant.
Drugs, chemicals, reagents and other materials
Exogenous K+ was added as an isotonic physiological salt solution in which all the
NaCl was replaced with an equivalent amount of KCl. Concentrations of K+ used
are expressed as final bath concentration. Ebselen (2-Phenyl-1,2-benzisoselenazol-
3(2H)-one), L-NAME (NG-nitro-L-arginine methyl ester), Nordihydroguaiaretic
acid (NDGA), papaverine HCl, PD 146176 (6,11-Dihydro[1]benzothiopyrano[4,3-
b]indole), tempol (4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl), TRAM-34
(1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole) and U46619 (9,11-Dideoxy-
11α,9α-epoxymethanoprostaglandin F2α) were all obtained from Sigma (Poole, U.K.).
Apamin and iberotoxin, from Latoxan (Valence, France). SLIGRL-NH2 (serine, leucine,
isoleucine, glycine, arginine, leucine) from Auspep (Parkville, Australia). 8-iso PGF2α
fromCayman-Europe(Tallinn,Estonia).tAUCB(trans-4-[4-(3-Adamantan-1-yl-ureido)-
cyclohexyloxy]-benzoic acid) was a generous gift from Professor Bruce D. Hammock
(University of California, Davis). All stock solutions (100 mM) were prepared in
dimethylsulfoxide(DMSO)exceptL-NAME,apamin,iberiotoxin,papaverineandSLIGRL
that were dissolved in 0.9% NaCl and tempol which was dissolved in ultrapure water.
Vehiclecontrolswereperformedwhennecessary.
RESULTS
Effect of LOX and sEH inhibition on EDH
In our previous studies, control arteries that had not been treated with a NOS inhibitor
demonstrate endothelium-dependent hyperpolarization (EDH) that has components
from KCa2.3, KCa3.1 and KCa1.1 channels (McNeish & Garland, 2007; McNeish et al.,
2006). A similar pattern was seen in this study. Control EDH was significantly inhibited
only by the combination of the KCa3.1 inhibitor TRAM-34 and the KCa2.3 inhibitor
apamin; TRAM-34 alone had no significant inhibition alone (Fig. 1B); apamin alone
was not assessed in this study but our previous studies demonstrate alone it does not
have a significant effect on EDH under these conditions (McNeish & Garland, 2007;
McNeish et al., 2006). The residual EDH was blocked by the inhibitor of KCa1.1 (BKCa),
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 5/19Figure 1 Effect of lipoxygenase inhibition on endothelium-dependent hyperpolarization (EDH) evoked by SLIGRL (20 µM) in rat middle
cerebral arteries that are able to synthesize NO. (A) An original, representative trace showing control EDH (upper panel) and the effect of the
non-selective lipoxygenase inhibitor NDGA (1 µM) on EDH (lower panel). Also shown are bar graphs showing (B) control EDH and the effect of
lipoxygenase inhibitors NDGA (C) and ebselen (1 µM) (D) as well as the effect subsequent inhibition of KCa3.1 (TRAM-34) KCa2.1 (apamin) and
KCa1.1 (iberiotoxin) on EDH. Control EDH was only inhibited following inhibition of KCa2.3 and KCa3.1 in the combined presence of apamin
and TRAM-34, respectively. NDGA and ebselen significantly inhibited EDH, the residual hyperpolarization was inhibited by TRAM-34 alone,
subsequent addition of apamin and IbTx had no significant additional effect. ∗P < 0.05 indicates a significant difference from control.
iberiotoxin. SLIGRL (20 µM) evoked EDH (−30.0±5.5 mV, n = 4) that was significantly
reducedbytheLOXinhibitornordihydroguaiaretic(NDGA,1µM;−10.7±2.3mV;n = 4,
P < 0.05; Figs. 1A and 1C). This hyperpolarization was further reduced by TRAM-34
(−4.3 ± 2.4 mV, n = 5) but not by subsequent additions of apamin and iberiotoxin
(Fig. 1B). NDGA also abolished spontaneous tone (1.9±0.6 vs 0.2±0.2 mN, pre- and
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 6/19post-NDGA, respectively, n = 4, P < 0.05). This relaxation was not associated with
significant hyperpolarization (Em −44.6±3.0 vs 51.9±4.3 mV, pre- and post-NDGA,
respectively, n = 4). A structurally distinct blocker of LOX, ebselen (10 µM), had similar
effects.EbselensignificantlyinhibitedEDH(−28.8±2.2mVvs−15.6±2.9mV,pre-and
post-ebselen, respectively; P < 0.05, n = 6; Fig. 1C). Hyperpolarization that was resistant
to ebselen was not significantly reduced by TRAM-34 (Fig. 1C) or further addition of
apamin but the subsequent addition of iberiotoxin reduced hyperpolarization further
(Fig. 1D). Ebselen also reduced spontaneous tone (0.6 ± 0.0 mN vs 0.3 ± 0.1 mN, pre-
and post-ebselen, respectively, n = 6,P < 0.05) that was not associated with significant
hyperpolarization(Em −44.3±1.0vs−49.0±3.3mV,pre-andpost-ebselen,respectively,
n = 6). A third LOX inhibitor, PD146176 (5 µM), also reduced EDH (−27.5 ± 3.1
and −9.8 ± 2.6 mV pre- and post-PD146176 respectively, n = 5,P < 0.05). PD146176
also reduced spontaneous tone (1.5 ± 0.3 and 0.2 ± 0.1 mN pre- and post-PD146176
respectively, n = 5,P < 0.05) that was not associated with significant hyperpolarization
(Em − 52.1 ± 3.9 vs −58.7 ± 4.5 mV, pre- and post-PD146176, respectively, n = 5).
The similar effect of these three structurally different LOX inhibitors to inhibit EDH
and abolish the KCa2.3 component of this response indicates a role for LOX-derived AA
metabolitesinEDH.
Previous studies indicate that the LOX-derived HEETA is metabolized by sEH to
THETA (Chawengsub et al., 2008). Inhibition of sEH reduced HEETA metabolism and
enhanced EDH to AA suggesting an important role for HEETA in mediating EDH.
The inhibitor of sEH, tAUCB (10 µM) did not significantly effect EDH to SLIGRL
in control vessels (−33.5 ± 5.4 vs 30.8 ± 6.0 mV pre- and post-tAUCB, respectively
n = 5). Following inhibition of KCa3.1 and KCa1.1 with the combination TRAM-34 and
iberiotoxin,theresidualhyperpolarizationtoSLIGRL(−17.8±2.8mV,n = 5)ismediated
solely by KCa2.3. Under these conditions, the KCa2.3-mediated hyperpolarization was
significantly augmented by tAUCB (−29.2±3.6, P < 0.05,n = 6, Figs. 2A and 2B). This
augmented response is specific for KCa2.3 since addition of apamin significantly inhibited
EDH (−7.0 ± 2.0 mV, P < 0.05, Figs. 2A and 2B). Therefore, an epoxide-containing
LOX metabolite of AA contributes to the KCa2.3 component of EDH and is normally
metabolizedbysEH.
Effect of tAUCB and superoxide scavenging on EDH responses in
the presence of L-NAME
In the presence of the NOS inhibitor L-NAME, inhibition of KCa3.1 alone abolishes EDH
(McNeish, Dora & Garland, 2005; McNeish et al., 2006). The absence of a KCa2.3 compo-
nentreflectsactivationofTPreceptors(McNeish&Garland,2007).Similarly,inthisstudy,
theisolatedEDH-mediatedresponseobtainedinthepresenceofL-NAME(hyperpolariza-
tionof23.1±4.6mVandrelaxationof74.3±5.3%,n = 8)wassignificantlyattenuatedby
TRAM-34 alone (hyperpolarization of −6.5±1.5 mV andrelaxation of 25.0±4.2%,n =
5; Fig. 2C). Application of tAUCB to TRAM-34-treated arteries failed to recover the EDH
response (hyperpolarization of −4.2 ± 2.4 mV and relaxation of 23.7 ± 2.7%,n = 5;
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 7/19Figure 2 The effect of the sEH inhibitor tAUCB on the KCa2.3 component of endothelium-dependent hyperpolarization (EDH) in rat middle
cerebral arteries able to synthesize NO. (A) Original traces of KCa2.3-mediated hyperpolarization obtained in the presence of: the KCa3.1
inhibitor TRAM-34 and KCa1.1 inhibitor iberiotoxin (upper trace), the subsequent addition of tAUCB (middle trace) and the combination of
tAUCB and the KCa2.3 inhibitor, apamin. (B) Bar graph showing control EDH, KCa2.3 dependent EDH in the presence and absence of tAUCB
and further addition of apamin. The KCa2.3-dependent hyperpolarization was significantly smaller than control EDH and was potentiated by
tAUCB this hyperpolarization was completely abolished by apamin indicating that it was mediated solely by KCa2.3. (C) Bar graph showing
the SLIGRL-induced EDH mediated hyperpolarization (left panel) and relaxation (right panel) in the presence of the NOS inhibitor L-NAME.
TRAM-34 significantly attenuated EDH responses and the subsequent addition of t-AUCB had no further effect. Under these conditions, there is
no contribution from KCa2.3 channels and tAUCB failed to restore the function of this channel. (D) Bar graphs showing the SLIGRL-induced EDH
mediated hyperpolarization (left panel) and relaxation (right panel) in the presence tempol and the NOS inhibitor L-NAME. Tempol restored a
KCa2.3 component to the EDH response and also revealed a KCa1.1 component (n = 5). ∗P < 0.05 indicates a significant difference from control,
ΨP < 0.05 indicates a significant difference from TRAM-34 + IbTx (KCa2.3 hyperpolarization).
Fig. 2C). In the combined presence of L-NAME and tempol, a cell permeable superoxide
scavenger,isolatedEDHresponsestoSLIGRLweresignificantlyinhibitedonlybythecom-
binationofTRAM-34andapamin.FurtherinhibitionofKCa1.1withiberiotoxinabolished
the residual EDH response (Fig. 2D). Thus, tempol restored the KCa2.3 component to the
EDHwhereasinhibitionofsEHfailedtorestorethiscomponentofEDH.
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 8/19Figure 3 Effect of the NOS inhibitor L-NAME on arachidonic acid metabolism by rat cerebral arter-
ies. Arteries were incubated with 14C-AA and indomethacin in the absence (A) and presence of L-NAME
(B). Metabolites were extracted and separated by reverse-phase HPLC, solvent system 1. Migration times
of known standards are shown on each chromatogram. CPM, counts per minute; THETA, trihydroxye-
icosatrienoic acid; HEETA, hydroxyepoxyeicosatrienoic acid; HETE, hydroxyeicosatetraenoic acid; AA,
arachidonic acid.
AA metabolism of the rat middle cerebral artery
Since LOX metabolites mediate a component of EDH, we investigated the metabolism of
14C-AA by cerebral arteries. In arteries treated with the COX inhibitor, indomethacin,
to facilitate the identification of LOX metabolites, the products of AA metabolism
were resolved by reverse phase HPLC using solvent system 1. 14C-Labelled metabolites
co-migratedwiththeLOXproductsTHETAs,HEETAs,15-HETEand12-HETE(Fig.3A).
There were virtually no AA metabolites eluting with the EETs indicating that it is unlikely
that the middle cerebral artery produces cytochrome P450 epoxygenase products. In the
presence of the NOS inhibitor L-NAME, there was a significant change in the profile of
AA metabolism. Metabolites co-migrating with 12-HETE and 15-HETE were markedly
increased whereas the metabolites co-migrating with the THETAs and HEETAs increased
slightly(Fig.3B).ArterieswerealsoincubatedinthepresenceandabsenceofL-NAMEand
the metabolites resolved by reverse phase HPLC using solvent system 2 that resolves COX
metabolitesandisoprostanes.Indomethacinwasnotpresentintheseincubations.Metabo-
lites comigrating with 6-keto PGF1α, 8-iso-PGF2 and 12-HETE were detected (Fig. 4). A
14C-metabolite comigrating with TxB2 was not observed. Following L-NAME treatment,
therewasalsoamarkedincreaseinpolarmetaboliteselutinginfractions5–10andpossibly
8-iso-PGF2, eluting in fractions 33–34 (Fig. 4). Isoprostane synthesis was confirmed by
LC/MS analysis. Extracts were purified by reverse phase HPLC using solvent system 3 and
the eluate monitored by selected ion monitoring of m/z 351 for PGE2-type isoprostanes
and m/z 353 for PGF2-type isoprostanes (Fig. 5). The production of 8-iso-PGE2 was
similar in control and L-NAME-treated arteries (380 and 335 ng/ml, respectively;
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 9/19Figure 4 Effect of L-NAME on arachidonic acid metabolism by rat cerebral arteries. Arteries were
incubatedwith 14C-labeledarachidonicacidintheabsence(control,solidline)andpresenceofL-NAME
(100mM)(dottedline).Metaboliteswereextractedandseparatedbyreverse-phaseHPLC,solventsystem
2. Migration times of known standards are shown on each chromatogram. CPM, counts per minute; PG,
prostaglandin; TX, thromboxane; HETE, hydroxyeicosatetraenoic acid; AA, arachidonic acid.
Figure 5 Effect of L-NAME on iso PGE2 and iso PGF2 production of rat cerebral arteries. Arteries
were incubated with AA and indomethacin in the absence and presence of L-NAME. Metabolites were
extracted and analyzed by liquid chromatography–mass spectrometry. Selected ion chromatogram m/z
351 (iso PGE2) (A) and m/z 353 (iso PGF2) (B). Migration times of known standards are shown on each
chromatogram. * indicates a marked change in production following treatment with L-NAME.
Fig. 5A), whereas 8-iso-PGF2 production increased 3-fold with L-NAME treatment
(179 and 583 ng/ml, respectively; Fig. 5B). In addition, several unidentified PGF2-type
isoprostaneswereproducedbycerebralarteriesandwereincreasedbyL-NAME(Fig.5B).
Effect of 8-isoprostane F2 on EDH
Since cerebral arteries synthesize isoprostanes, and L-NAME increased their production,
we investigated the effects of 8-iso-PGF2 on vascular tone and EDH. 8-iso-PGF2 caused
concentration-dependentcontractionofcerebralarteriesthatwasfullyinhibitedbytheTP
receptorantagonistSQ29,548(10µM,Fig.6A).
In control vessels, exogenous application of 8-iso-PGF2 (1 µM) caused significant
depolarizationandconstriction(Em −49.9±2.5vs−40.7±2.5mVandtension1.0±0.2
vs 3.9 ± 0.3 mN pre- and post-8-iso-PGF2, respectively, n = 9,P < 0.05) but did not
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 10/19Figure 6 Effect of isoprostane F2α (8-iso PGF) on middle cerebral arteries. (A) Concentration-response curve showing constriction produced by
8-iso PGF in rat middle cerebral arteries that were able to synthesize NO. This constriction was completely blocked by the selective TP antagonist SQ
29,543. (B) Original traces showing the effect of pre-incubation of 8-iso PGF2 on EDH evoked by SLIGRL (20 µM) in rat middle cerebral arteries
that were able to synthesize NO. 8-iso PGF2 did not significantly affect control EDH (upper panel) but subsequent inhibition of KCa2.3 (TRAM-34;
1 µM) virtually abolished EDH (lower panel). The vessel viability was assessed by addition of 15 mM K+ which evokes endothelium-independent
hyperpolarization and relaxation. (C) Bar graph showing the effect of 8-iso PGF on EDH. Control EDH is unaffected by 8-iso PGF, TRAM-34 alone
significantly inhibited EDH and apamin is without effect. The combination of apamin and TRAM-34 had no further effect to TRAM-34 alone.
The data shows that 8-iso PGF2 inhibits the KCa2.3 component of EDH normally seen under these conditions. ∗P < 0.05 indicates a significant
difference from control. ΨP < 0.05 indicates a significant difference from 8-iso-PGF2α.
significantly affect SLIGRL-induced EDH (−28.0 ± 2.7 vs 23.7 ± 2.3 mV, pre- and
post-8-iso-PGF2 respectively,n = 9;Figs.6Band6C).Inthepresenceof8-iso-PGF2,EDH
was significantly inhibited by TRAM-34 alone (−13.6±2.8 mV, P < 0.05,n = 5; Figs. 6B
and 6C) whereas apamin alone had no effect (−25.5±5.9 mV, n = 4; Fig. 6C); nor did it
haveanyadditionalaffectincombinationwithTRAM-34(−9.6±1.1mV,n = 9;Fig.6C).
The residual hyperpolarization was blocked by addition of iberiotoxin (−3.2±0.8 mV,
n = 7;Fig.6C).
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This study is the first to demonstrate that a LOX metabolite(s) of AA, contributes to
endothelium-dependent hyperpolarization (EDH) in the rat middle cerebral artery and
thus may be the, as yet, unidentified AA metabolite involved in EDH responses in the
middle cerebral artery. Following inhibition of NOS with L-NAME, the profile of AA
metabolism is altered. There is no change in production of LOX products; however,
L-NAMEincreased8-iso-PGF2 productionandtheproductionofotheriso-PGF2 isomers.
We suggest that the increase in isoprostane formation causes the TP receptor-dependent
lossofKCa2.3-mediatedcomponentofEDH,aphenomenonwehadpreviouslyattributed
toTxA2 (McNeish&Garland,2007).
The findings that 15-LOX metabolites, namely HEETA and THETA, contribute to
the EDH response in rabbit arteries lead us to investigate whether these metabolites
contributed to EDH in the rat middle cerebral artery. This was of particular interest
as EDH responses in this artery have a component dependent upon an unidentified
AA metabolite (McNeish & Garland, 2007; You, Golding & Bryan, 2005). Analysis of AA
metabolism by the middle cerebral artery indicates LOX products are generated whereas
epoxygenase metabolites such as EETs are not. In control arteries, EDH induced by
SLIGRL-NH2 is significantly attenuated by three structurally distinct inhibitors of LOX
enzymes. These findings clearly indicate that EDH in this artery is mediated, at least in
part,byLOXmetabolites.
KCa channelsmediatetheEDHresponsestoLOXmetabolites;themostlikelycandidates
are either 12-HETE, a 12-LOX metabolite, (Zink et al., 2001) or HEETA and THETA,
15-LOXmetabolites(Campbelletal.,2003;Chawengsubetal.,2008;Chawengsub,Gauthier
& Campbell, 2009). These metabolites are all produced by the rat middle cerebral artery
consistent with the expression of a 12/15-LOX. Interestingly, 12-HETE (30 nM) had no
effect on membrane potential or tone in cerebral arteries (data not shown). Therefore, the
15-LOXproducts,HEETAorTHETA,aremostlikelytheAAmetabolitesthatcontributeto
EDHresponsesinthisartery.
HEETAandTHETAstimulatehyperpolarizationofrabbitarteriesbydirectstimulation
of KCa2.3 (Campbell et al., 2003; Chawengsub et al., 2008). As HEETA is rapidly
metabolized by sEH to THETA, it is difficult to distinguish between the activities of these
two eicosanoids. In order to ascertain which of these metabolites contributes to EDH, we
used a selective sEH inhibitor tAUCB (Liu et al., 2009); tAUCB does not affect total EDH
but selectively augments the KCa2.3 component of EDH. As inhibition of sEH prevents
the rapid breakdown of HEETA to THETA, it is likely that the HEETA, not THETA, is the
15-LOX product involved in EDH. In rabbit arteries, both these LOX products directly
stimulateKCa2.3locatedontheSMClayerandthusactasdiffusibleEDHFs.However,such
an action is unlikely in the rat middle cerebral artery as KCa2.3 are expressed solely on the
endothelium (Cipolla et al., 2009; McNeish et al., 2006). Thus, it is more likely that HEETA
contribute to EDH by acting as an intracellular or autocrine modulators of endothelial
KCa2.3, as proposed for other AA metabolites involved in EDH responses such as EETs
(Campbell & Falck, 2007; Edwards, Feletou & Weston, 2010). More recently, metabolites
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 12/19of AA have also been shown to have effects on transient receptor potential channels
evoking subsequent KCa channel activation and dilation (Earley, 2011; Sonkusare et al.,
2012;Zhengetal.,2013).
Under the experimental conditions described above, the middle cerebral artery pro-
duces NO and the KCa2.3 channel contributes to EDH. However, under conditions where
NOS is blocked to observe the EDH response in isolation, the KCa2.3 channel component
of hyperpolarization is lost and only KCa3.1 channels contribute to the EDH response
(Marrelli, Eckmann & Hunte, 2003; McNeish, Dora & Garland, 2005; McNeish et al., 2006).
The loss of the KCa2.3 channel component involves stimulation of TP receptors (McNeish
& Garland, 2007). Since LOX products appear to selectively augment KCa2.3 channels, we
postulated that TP-mediated inhibition of this channel may be due to a reduction in LOX
metabolites. However, following NOS inhibition, there was actually an increase in the AA
metabolitescorrespondingtoHEETA,THETAandHETEs.InhibitionofsEH(atreatment
thatwouldbeexpectedtoprotectHEETAproductionandthusKCa2.3channelactivation)
failed to restore KCa2.3 channel function when NOS was inhibited. Therefore, loss of
KCa2.3 function following NOS inhibition does not involve decreased production of LOX
metabolites. This finding supports a previous study that demonstrated inhibition of LOX
hasnoeffectonEDHresponsesfollowinginhibitionofNOS(You,Golding&Bryan,2005).
A potential explanation for the loss of KCa2.3 channel function following NOS
inhibition,despiteincreasedproductionofLOXmetabolites,isthatTPmediatedsignaling
mechanisms overcome the actions of LOX metabolites. TP receptor stimulation inhibits
KCa2.3-mediatedresponsesincontrolarteriesabletosynthesizeNO(McNeish&Garland,
2007)by aRho kinasedependent mechanism(McNeishet al.,2012). Therefore,wewished
to confirm that synthesis of the endogenous activator of TP receptors, TxA2, is increased
following NOS synthase inhibition, as previously suggested (McNeish & Garland, 2007).
Surprisingly, we did not detect TxA2 production with, or without, NOS inhibition.
However, following NOS inhibition there was an increase in production of isoprostanes
whichalsostimulateTPreceptors(Crankshaw,1995;Elmhurst,Betti&Rangachari,1997).
The most likely source of isoprostanes is the non-enzymatic reaction of either free or
esterified AA with reactive oxygen species such as superoxide (Morrow et al., 1990). Due
to our sampling technique of measuring isoprostanes in the incubation medium it is
likely that we were measuring isoprostanes produced from free AA (although we cannot
eliminate the possibility that esterified isoprostanes were also released into the medium);
however the endothelium is the mostly likely source of the isoprostanes as it is the major
source of AA metabolites in vascular tissues (Rosolowsky & Campbell, 1993; Rosolowsky &
Campbell, 1996). Interestingly, superoxide production is high in the cerebral vasculature
whencomparedtosystemicvesselsduetoincreasedexpressionofNADPHoxidase(Miller
et al., 2005). As NO reacts rapidly with superoxide, it is conceivable NOS inhibition in
the middle cerebral artery increases free superoxide produced from NADPH oxidase and
therefore isoprostane synthesis leading to stimulation of TP receptors and loss of KCa2.3
function. The superoxide scavenger tempol prevented loss of KCa2.3 function following
inhibition of NOS supporting this hypothesis. Furthermore, using LC/MS, we detected
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 13/19Figure 7 Schematic showing the role of LOX products on EDH responses in the middle cerebral
artery, the proposed effect that inhibition of NOS and increase in isoprostane production has on the
EDH response. (1) Under conditions where middle cerebral arteries can synthesize NO, metabolism
of AA by LOX produces HEETA which is metabolized by sEH to THETA. Both can activate KCa2.3
channels. As tAUCB augments the KCa2.3 response HEETA is likely to be the metabolite involved. (2)
Under these conditions the EDH response also involves activation of KCa3.1 and KCa1.1 channels to
produce smooth muscle cell hyperpolarization and relaxation. (3) When NO is synthesized (4) it rapidly
reacts with superoxide preventing production of isoprostanes, when NOS is inhibited (5) this inhibitory
effect of NO on isoprostane production is reduced. Endothelial cells are the major source of vascular AA
metabolites but it is possible NO prevents isoprostane production in SMCs. The subsequent stimulation
of the TP receptor (6) inhibits the KCa2.3 component of EDH as we have previously reported (McNeish
& Garland, 2007; McNeish et al., 2012). Solid lines/arrows represent known pathways, dashed lines
indicate possible/unconfirmed pathways, green arrows are stimulatory pathways, red lines/text represent
inhibitory pathways/blocking agents. EC, endothelial cell; SMC, smooth muscle cell.
increasedproductionof8-iso-PGF2 andseveralasyetunidentifiedPGF2-typeisoprostanes
following NOS inhibition. While the source of superoxide was not investigated in this
study a similar increase in isoprostane production following inhibition of NOS has been
observed kidneys where it was reversed by tempol and knock out of gp91 phox (Haque &
Majid, 2008; Kopkan & Majid, 2006), we thus speculate that a similar NADPH dependent
mechanism is responsible for increased isoprostane production in cerebral arteries. In
arteries not treated with a NOS inhibitor, exogenous 8-iso-PGF2 constricted the middle
cerebral artery via a TP receptor dependent mechanism and mimicked the ability of other
TPreceptoragonists(McNeish&Garland,2007)toinhibittheKCa2.3componentofEDH.
Thus, increased production of 8-iso-PGF2 following NOS inhibition is likely to cause the
lossoftheKCa2.3componentofEDH.
ThedataaresummarizedinFig.7,theyindicatethenovelfindingthatLOXmetabolites
of AA, most likely HEETA, contribute to EDH in the middle cerebral artery and that
inhibition of sEH with the selective inhibitor tAUCB increases the KCa2.3 component of
Gauthier et al. (2014), PeerJ, DOI 10.7717/peerj.414 14/19hyperpolarization. However, the loss of KCa2.3 function following inhibition of NOS is
not restored by tAUCB treatment. Instead, NOS inhibition increases F-type isoprostane
production resulting in TP receptor stimulation (Fig. 7), the loss of KCa2.3 responses and
elimination of the effect of HEETA. These findings may have important implications in
diseases associated with loss of NO signaling such as stroke and coronary artery disease
where increased isoprostane production has been detected (Patrono & FitzGerald, 1997).
This pathway may be related to the severity of the disease (Wang et al., 2006). Our data
indicate that inhibition of sEH may not be an effective treatment for cerebrovascular
diseasebutpreventionofisoprostaneformationmaybebeneficial.
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